Press releases

25 Jul 2024

Strong Start into UCB’s Decade of Growth

28 Jun 2024

Acquisition of own shares

28 Jun 2024

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

26 Jun 2024

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

14 Jun 2024

Acquisition of own shares

13 Jun 2024

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

Press releases

Press releases

Search Press releases

Strong Start into UCB’s Decade of Growth

Acquisition of own shares

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

Acquisition of own shares

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Strong Start into UCB’s Decade of Growth

Acquisition of own shares

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

Acquisition of own shares

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

Choose a Country